American Society of Hirudotherapy

H. medicinalis Saliva Mass-Spectrometry Characterization (2024)

2024 LC-MS/MS proteomic analysis of lyophilised medicinal-leech saliva extract with an in vitro macrophage assay — Ayhan 2024.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Last Updated: May 28, 2026 · ASH Editorial · based on the books

Mechanistic Evidence Box

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.
Page type
Compound profile
Evidence type
Preclinical / biochemical characterization
Evidence level
Mechanistic discussion
Drug vs leech
Leech-derived crude extract

Clinical translation limit

Descriptive proteomic inventory does NOT establish clinical efficacy. Individual factors require independent functional + clinical characterization. The K040187 device clearance covers whole-leech device use, not isolated proteins.

Molecular Profile

Category
Other
Evidence tier
Preclinical
Source species
Hirudo medicinalis
Discovered
2024 · Ayhan H et al.

Biological Targets

  • → composite secreted-saliva proteome catalogue (multi-target)

Key Citations

  1. Ayhan H et al. (2024), Immunol Res · PMID 39671012

External Resources

    Related Other Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.